Hematologic Malignancies Demystified - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Hematologic Malignancies Demystified

Downloadable Slides From a 2018 prIME Oncology Meeting Series

Not a member of My prIME? Join now for instant access.

prIME Downloadable Slides from the 2018 Hematologic Malignancies Demystified Series.

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Feb 21, 2018

Expiration Date

Feb 21, 2019

Featured Expert

  • Richard M. Stone, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

Acute Leukemia

Featured Expert

  • Guillermo Garcia-Manero, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Myelodysplastic Syndromes

Featured Expert

  • Srdan Verstovsek, MD, PhD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Myeloproliferative Neoplasms

Featured Expert

  • Jorge Cortes, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Chronic Myelogenous Leukemia

Featured Expert

  • Barbara Pro, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States

Featured Topic

Hodgkin Lymphoma

Featured Expert

  • Julie Vose, MD, MBA, University of Nebraska Medical Center, Omaha, Nebraska, United States

Featured Topic

Non-Hodgkin Lymphoma

Featured Expert

  • Susan O'Brien, MD, UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange, California, United States

Featured Topic

Chronic Lymphocytic Leukemia

Featured Expert

  • Sagar Lonial, MD, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

Featured Topic

Multiple Myeloma

Featured Expert

  • Sergio Giralt, MD, FACP, Memorial Sloan Kettering Cancer Center, New York, New York, United States

Featured Topic

Complications of Transplant

Featured Expert

  • Stephan Moll, MD, University of North Carolina, School of Medicine, Chapel Hill, North Carolina, United States

Featured Topic

Benign Hematology

This educational activity is specifically designed for practicing medical oncologists, hematologists, registered nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in and/or involved in the treatment of patients with cancer in the US.

After successful completion of this educational activity, participants should be able to:

Physicians

  • Assess new and emerging data with established treatment options
  • Evaluate safety and efficacy data from recent and ongoing clinical trials
  • Distinguish the adverse event profiles of different options for hematologic malignancies
  • Evaluate expert recommendations for monitoring treatment response and managing adverse events

Nurses

  • Evaluate safety and efficacy data from recent and ongoing clinical trials
  • Identify the most common treatment-associated side effects in hematologic treatment agents and select appropriate strategies for prevention, recognition, and management of these events
  • Evaluate the clinical evidence for, and counsel patients on the importance of, the utilization of cytogenetic markers, minimal residual disease, and other prognostic/predictive tests

This educational activity is supported by grants from AbbVie Inc.; Bayer HealthCare Pharmaceuticals, Inc.; Celgene Corporation; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Novartis Oncology; Seattle Genetics, Inc.; and Takeda Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Anderson discloses that he has received consulting fees from Bristol-Myers Squibb, Celgene, and Millennium. He also disclosed participation in a Gilead scientific advisory board, and ownership interest and intellectual property rights as the scientific founder of C4 Therapeutics and OncoPep. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Arellano discloses that she has performed contracted research or received research support from Cephalon Oncology. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Cortes discloses that he has received consulting fees from Bristol-Myers Squibb, Fusion, Novartis, Pfizer, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cutler discloses that he has received consulting fees from Incyte and Pharmacyclics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Garcia-Manero has no relevant financial relationship to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Giralt discloses that he has received fees for consulting and independent contracting from Amgen, Jazz, Sanofi, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gopal discloses that he has received consulting fees from Adaptive, Aptevo, BRIM Pharmaceuticals, Janssen, and Seattle Genetics.  He also discloses independent contracting for Bristol-Myers Squibb, Gilead, Incyte, Janssen, Merck, Pfizer, Seattle Genetics, Spectrum, Takeda, Teva, and TG Pharmaceuticals. He also discloses ownership interest in Complement.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kantarjian discloses that he has received honoraria for promotional speaker’s bureaus from AbbVie, Actinium, Amgen, Ariad, Bristol-Myers Squibb, Immunogen, Orsinex, and Pfizer. He also discloses independent contracting for Novartis and Pfizer, and receipt of research grants from Amgen, Ariad, Astex, and Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Kebriaei has no relevant financial relationship to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Lonial discloses that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, and Takeda. He also discloses performing contracted research or receiving research support from Bristol-Myers Squibb, Celgene, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mato discloses that he has received consulting fees from AbbVie, AstraZeneca, Celgene, Gilead, Janssen, and Pharmacyclics. He also discloses membership on advisory committees or review panels for Gilead, Pharmacyclics, and TG Therapeutics. He also discloses independent contracting for AbbVie, AstraZeneca, Celgene, and Johnson & Johnson. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mesa discloses that he has received consulting fees from AOP, Novartis, and Shire. He has also disclosed independent contracting for Celgene, CTI, Gilead, and Incyte. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Moll discloses that he has received consulting fees from Portola Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Moskowitz discloses that he has received consulting fees from Celgene, Genentech, Merck, and Seattle Genetics. He has also disclosed independent contracting for Merck, Pharmacyclics, and Seattle Genetics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr O’Brien discloses that she has received consulting fees from AbbVie; Alexion; Amgen; Aptose Biosciences, Inc.; Astellas; Celgene; Gilead; GlaxoSmithKline; Janssen Oncology; Pfizer; Pharmacyclics; Sunesis; TG Therapeutics; and Vaniam Group LLC. She has also received research support from Acerta, Gilead, Kite, Pfizer, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Pro discloses that she has received consulting fees from Celgene, Portola, Seattle Genetics, and Takeda.  She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Seiter discloses that she has received honoraria for promotional speaker’s bureaus from Alexion, Amgen, Celgene, Incyte, Novartis, and Seattle Genetics. She also discloses independent contracting for Astellas, Celator, Celgene, Daiichi-Sankyo, Forma, Incyte, Onconova, and Seattle Genetics, and has been a member of an advisory committee or review panel for Astellas and Shire. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Stone discloses that he has received consulting fees from AbbVie, Agios, Amgen, Argenx, Arog, Astellas, Celator, Celgene, Cornerstone, Fujifilm, Janssen, Jazz, Juno, Karyopharm, Merck, Novartis, Ono, Orsenix, Otsuka, and Pfizer. He also discloses receipt of research funding from Agios and Novartis, and has served as a board member and advisory committee member for Actinium. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Venugopal discloses that he has received consulting fees from AbbVie Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Verstovsek discloses that he has received research support from AstraZeneca, Blueprint Medicines Corporation, Bristol-Myers Squibb, Celgene, CTI BioPharma Corporation, Galena BioPharma, Genentech, Gilead, Incyte Corporation, Lilly Oncology, Ns Pharma, Pfizer, Promedior, Roche, and Seattle Genetics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vose discloses that she has received honoraria from AbbVie, Epizyme, Legend Pharmaceuticals, Novartis, and Roche. She also discloses that she has received research grant support from Acerta Pharma; Bristol-Myers Squibb; Celgene; Incyte Corporation; Kite Pharma; Merck Sharp and Dohme Corporation; Novartis; and Seattle Genetics, Inc. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.